Clin Psychopharmacol Neurosci 2018; 16(4): 497-500  
Clinical Usefulness of Aripiprazole Treatment in a Girl with Prader-Willi Syndrome and Psychosis
Wolfgang Briegel
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Leopoldina Hospital, Schweinfurt, Germany
Correspondence to: Wolfgang Briegel, Priv.-Doz. Dr. med. habil.
Klinik für Kinder- und Jugendpsychiatrie, Psychosomatik & Psychotherapie, Leopoldina-Krankenhaus, Gustav-Adolf-Str. 4, 97422 Schweinfurt, Germany
Tel: +49-9721-720-3370, Fax: +49-9721-720-2901
E-mail: wbriegel@leopoldina.de
ORCID: https://orcid.org/0000-0002-8253-5070
Received: February 7, 2017; Revised: May 3, 2017; Accepted: May 10, 2017; Published online: November 30, 2018.
© The Korean College of Neuropsychopharmacology. All rights reserved.

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Prader-Willi syndrome (PWS) is a quite rare multi-systemic genetic disorder strongly associated with psychiatric illness in adults, especially psychosis. This report presents a 16-year-old female with PWS and symptoms of brief psychotic disorder with a complete resolution of symptoms under aripiprazole medication. However, an exacerbation occurred after aripiprazole reduction. Apart from a weight gain of about 2 kg over the course of two years, no adverse effects could be found. This first report on the use of aripiprazole in a subject with PWS and psychosis suggests that aripiprazole might be a promising treatment approach in this distinct group of patients.
Keywords: Prader-Willi syndrome; Aripiprazole; Psychosis; Adolescent; Case reports.


This Article


Cited By Articles
  • CrossRef (0)

Author ORCID Information

Services
Social Network Service

e-submission

Archives